CORT
What one share of Corcept Therapeutics holds
Pharmaceutical Preparations
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.
Corcept Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $7.04 |
|---|---|
| Profit | $0.46 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $0.91 |
| Cash and investments | $5.04 |
| Book value | $6.53 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.70 | $0.07 | $0.00 | $0.16 | — | $0.37 |
| 2017 | $1.28 | $1.04 | $0.00 | $0.49 | — | $1.66 |
| 2018 | $1.98 | $0.60 | $0.00 | $0.91 | — | $2.40 |
| 2019 | $2.50 | $0.77 | $0.01 | $1.10 | — | $3.24 |
| 2020 | $2.85 | $0.85 | $0.01 | $1.21 | — | $4.48 |
| 2021 | $2.91 | $0.89 | $0.00 | $1.33 | — | $3.55 |
| 2022 | $3.47 | $0.87 | $0.00 | $1.03 | — | $4.65 |
| 2023 | $4.32 | $0.94 | $0.00 | $1.13 | — | $4.90 |
| 2024 | $5.95 | $1.23 | $0.02 | $1.73 | — | $6.47 |
| 2025 | $6.35 | $0.82 | $0.00 | $1.18 | — | $6.11 |